LONDON and NEW YORK, Sept. 17,
2021 /PRNewswire/ -- Trellus Health plc (AIM: TRLS),
which is commercialising a scientifically validated,
resilience-based, connected health solution for chronic condition
management, is pleased to announce that it has signed an agreement
to provide an Inflammatory Bowel Disease ("IBD") demonstration
programme for the Mount Sinai Health System ("Mount Sinai") employee health plan (the
"Agreement"), one of the largest self-insured employer health plans
in New York State.
As outlined in the Company's Admission Document, Trellus Health
intends to begin generating revenue in the current year through a
number of demonstration projects, potentially involving several
hundred patients in aggregate. This initial Agreement will assess
feasibility, engagement and satisfaction of the Company's digital
chronic condition management solution for Mount Sinai's non-union employees, eligible
dependents and their treating physicians.
Under the Agreement, Trellus Health will recruit, assess and
engage eligible IBD patients, with a targeted total enrolment of 25
patients. Following enrolment, the demonstration programme will
coordinate six months of active care management followed by a final
programme report, expected to be available within 30 days of
programme completion. This initial demonstration programme is
expected to commence before the end of 2021 with conclusions from
the final programme report expected in 2022.
The solutions deployed in this and other planned demonstration
programmes will utilise the scientifically validated patent-pending
GRITTTM resilience assessment and personalized care
management methodology and a proprietary technology platform
called TrellusElevate™, to coordinate and deliver personalised
clinical and behavioural care remotely via telehealth. The Company
expects to scale its initial demonstration projects into
longer-term and broader-ranging contracts based on the achievement
of successful IBD patient and physician engagement and satisfaction
rates.
The Company continues to engage with prospective partners and
customers on additional demonstration programmes. These are being
designed to illustrate the potential health economics and return on
investment to payers of the Company's digital chronic condition
management solutions and generate data to drive demand for greater
adoption, whilst simultaneously generating additional revenues for
the Company. Previous studies with IBD patients demonstrated
significant improvements in resilience and reductions in unplanned
healthcare by utilizing the Company's proprietary methodology and
resilience-driven multidisciplinary care model. The Directors
estimate that chronic and mental health conditions and IBD,
represent over $3 trillion and
$30-50 billion in total annual costs
in the US, respectively.
Trellus Health is initially focused on IBD, which includes the
chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and
demand across many chronic conditions including Irritable Bowel
Syndrome ("IBS"), diabetes, cancer, kidney disease, cardiac,
respiratory and autoimmune conditions. The Company will
utilize the GRITTTM resilience assessment and
personalized care management methodology, which were validated on
IBD patients at the Susan and Leonard Feinstein IBD Clinical Center
at The Mount Sinai Hospital, where Crohn's disease was first
identified by Dr. Burrill B. Crohn, MD in 1932.
Jane Maksoud, RN, MPA, Chief
Human Resources Officer, Mount Sinai Health System,
said: "We are pleased to offer our hard-working
faculty and staff innovative tools and programmes to improve their
health and overall well-being. We look forward to evaluating
Trellus Health as a potential new programme to address both
physical and mental resilience for improved employee health and
wellness."
Monique Fayad, Chief Executive
Officer, Trellus Health, commented: "Our commitment to
coordinating expert whole-person care for people living with
chronic conditions, addressing clinical and behavioral health
together, in context, is strategically aligned with the Mount Sinai
Health System's goal of rolling out new initiatives that transform
their employees in mind, body and spirit.
"We are delighted to be partnering with Mount Sinai, one of the largest self-insured
employers in New York state, to
demonstrate the feasibility of Trellus Health's resilience-based
digital care management solution for their employees living with
IBD."
The GRITTTM resilience assessment and
personalized treatment methodology described is based on
technology developed by Mount
Sinai faculty and licensed to Trellus Health. Mount Sinai and Mount Sinai faculty, including Marla Dubinsky, MD, and Laurie Keefer, PhD, have a financial interest in
Trellus Health. Mount Sinai has
representation on the Trellus Health Board of Directors.
About Trellus Health plc (www.trellushealth.com)
Trellus Health (LSE: TRLS) is a leading pioneer in
resilience-driven care and the first digital health company focused
on the intersection of chronic physical conditions and mental
health. Trellus Health's digital-first chronic care management
solution integrates convenient access to a licensed
multidisciplinary care team with a suite of tools for resilience
assessment, education and behavior modification, remote monitoring,
health maintenance and prevention. Through its
TrellusElevateTM connected care platform and
companion App, the company coordinates expert whole-person care,
addressing both clinical and behavioral health together, in
context, to improve outcomes and reduce healthcare costs for
patients, employers, and the healthcare system.
Trellus Health is commercialising the provision of digital
chronic condition management solutions for employers and health
plans that utilise the scientifically validated resilience-based
methodology and a proprietary HIPAA-compliant technology platform
called TrellusElevate™ to coordinate and deliver personalised care
remotely via telehealth. The Company is initially focused on
Inflammatory bowel disease ("IBD"), which includes the
chronic incurable conditions of Crohn's Disease and ulcerative
colitis, but considers its approach to have potential utility and
demand across many chronic conditions.
The TrellusElevate™ platform is the Company's proprietary
connected health platform that incorporates the proprietary
methodology and learnings on resilience from clinical research and
practice conducted at the Mount Sinai IBD Center for more than five
years. The proprietary methodology and resilience-driven
multidisciplinary care model have been scientifically validated to
demonstrate meaningful improvements in patient outcomes and over 85
per cent. reduction in unplanned healthcare utilisation (emergency
department visits and hospitalisations) which the directors of the
Company believe indicates the potential for significant cost
savings for healthcare payers.
The company was founded by Dr. Marla C.
Dubinsky, MD and Dr. Laurie
Keefer, PhD, both with decades of combined experience in IBD
and psychogastroenterology, respectively. Trellus Health's
patent-pending GRITTTM resilience assessment and
personalized treatment methodology was developed and validated at
the Mount Sinai Health System to build resilience and wellness for
improved outcomes at lower cost.
Shares in Trellus Health were admitted to trading on AIM in
May 2021, under the ticker
TRLS. For more information on Trellus Health,
visit www.trellushealth.com.
About the Mount Sinai Health System:
The Mount Sinai
Health System is New York City's
largest academic medical system, encompassing eight hospitals, a
leading medical school, and a vast network of ambulatory practices
throughout the greater New York
region. Mount Sinai is a national
and international source of unrivaled education, translational
research, and discovery, and collaborative clinical leadership
ensuring that we deliver the highest quality care—from prevention
to treatment of the most serious and complex human diseases.
The Mount Sinai Health System includes more than 7,200
physicians and features a robust and continually expanding network
of multispecialty services, including more than 400 ambulatory
practice locations throughout the five boroughs of New York City, Westchester, and Long Island.
The Mount Sinai Hospital is ranked No. 14 on U.S. News &
World Report's "Honor Roll" of the Top 20 Best Hospitals in the
country and the Icahn School of Medicine as one of the Top 20 Best
Medical Schools in the country. Mount Sinai Health System hospitals
are consistently ranked regionally by specialty and our physicians
in the top 1% of all physicians nationally by U.S. News & World
Report.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trellus-health-first-demonstration-contract-with-mount-sinai-employee-health-plan-for-resilience-based-digital-chronic-condition-management-301378736.html
SOURCE Trellus Health